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Abstract
Background—Red blood cell (RBC) folate concentrations are a potential biomarker of folate-
sensitive neural tube defect (NTD) risk in the population. The purpose of this analysis was to 
describe women in the U.S. population with RBC folate concentrations below those associated 
with optimal NTD prevention.
Methods—We used data from the 2007 to 2012 National Health and Nutrition Examination 
Survey (NHANES) to assess the RBC folate status of U.S. women of childbearing age relative to 
risk categories for NTD risk based on RBC folate concentrations. We defined suboptimal RBC 
folate concentrations as those associated with a prevalence of _9 NTDs per 10,000 live births.
Results—Among nonpregnant women age 12 to 49 years, 22.8% (95% Confidence Interval: 
21.1, 24.6) had suboptimal RBC folate concentrations. Women had greater odds of having a 
suboptimal RBC folate concentration if they did not use dietary supplements containing folic acid; 
had mandatorily fortified enriched cereal grain products as their only source of folic acid; were 
non-Hispanic black or Hispanic; or were current smokers.
Conclusion—Based on RBC folate concentrations, we would predict that the majority of U.S. 
women of reproductive age are not at increased risk for folate sensitive NTDs in the presence of 
mandatory folic acid fortification. Prevention policies and programs can be aimed at population 
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subgroups identified as having higher predicted risk for folate-sensitive NTDs based on RBC 
folate concentrations.
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Introduction
Periconceptional folic acid intake has been shown to prevent neural tube defects (NTDs), 
including spina bifida, anencephaly and encephalocele, in multiple settings, including 
randomized controlled trials, community prevention programs and through the evaluation of 
the impact of mandatory fortification of staple grains (MRC Vitamin Study Research Group, 
1991; Czeizel and Dudas, 1992; Berry et al., 1999; Williams et al., 2005; De Wals et al., 
2007; Sayed et al., 2008). In the United States, folic acid intake comes from three sources: 
enriched cereal grain products (ECGP); ready-to-eat (RTE) cereals, and folic acid-
containing dietary supplements. ECGP are grain products that are labeled “enriched” and are 
required to be fortified with 140 mg of folic acid per 100 g (U.S. Food and Drug 
Administration, 1996b). It has been estimated that mandatory fortification of ECGP 
increased the average daily usual intake of folic acid by _138 mg/day among U.S. adults 
(Yang et al., 2010). RTE cereal is permitted but not required to contain up to 400 mg of folic 
acid per serving (U.S. Food and Drug Administration, 1996a). In the United States, standard 
multivitamins generally contain 400 mg to 800 mg of folic acid, but doses up to 1000 mg are 
allowed without a prescription (Hendler and Rorvik, 2001). Recently, red blood cell (RBC) 
folate concentrations have been shown to be a generalizable biomarker of folate-sensitive 
NTD risk in populations. Studies in Ireland and China have shown that the risk of NTD-
affected pregnancy increases substantially as RBC folate concentrations decrease (Daly et 
al., 1995; Crider et al., 2014). The purpose of our analysis was to describe the population of 
U.S. women of childbearing age with RBC folate concentrations below those associated 
with optimal NTD prevention (WHO, 2015).
Materials and Methods
NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES), 2007 TO 2012
NHANES data are collected in 2-year phases using a stratified multistage probability design 
to capture a nationally representative sample of the noninstitutionalized civilian U.S. 
population. We used data from the 2007 to 2008, 2009 to 2010, and 2011 to 2012 phases for 
this analysis. NHANES methods are described in detail elsewhere (National Center for 
Health Statistics; National Center for Health Statistics; National Center for Health 
Statistics); briefly, NHANES includes a questionnaire administered in person at the home 
and a physical examination at a Mobile Examination Center (MEC). Our analysis focused 
on nonpregnant women of childbearing age, which we defined as 12 to 49 years. There were 
a total of 6433 women aged 12 to 49 years in NHANES 2007 to 2012. We excluded 182 for 
positive pregnancy status, an additional 164 who did not attend the MEC, an additional 416 
for whom RBC folate concentration was missing, and 1 who reported that she did not know 
the number of supplements that she took, leaving 5670 women available for most analyses. 
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In the analyses in which folic acid sources were considered, an additional 296 were excluded 
for unreliable (N58) or missing (N = 5288) day 1 dietary recall information and an 
additional 591 were excluded based on unreliable (N = 516) or missing (N = 5575) day 2 
dietary recall information, leaving 4783 women available for analyses.
We analyzed survey data using MEC sampling weights, with the exception of data for folic 
acid intake sources, for which we used day 2 dietary weights, as recommended by the 
National Center for Health Statistics (Johnson et al., 2013). NHANES is approved by the 
National Center for Health Statistics Research Ethics Review Board. All participants in 
NHANES provide written informed consent.
RED BLOOD CELL (RBC) FOLATE CONCENTRATIONS
Data on RBC folate concentrations came from analysis of blood samples collected at the 
MEC. RBC folate concentrations were measured in NHANES using the microbiologic assay 
method from 2007 to 2012 (National Center for Health Statistics; National Center for Health 
Statistics; National Center for Health Statistics). RBC folate concentrations are not normally 
distributed; therefore, we log transformed these values before analysis.
We defined cut-points for NTD risk categories based on RBC folate concentrations from 
publications by Daly et al. (1995) and Crider et al. (2014) (Table 1). The technique used for 
the microbiologic assay in these studies differed from that used in NHANES. We applied a 
conversion formula (To convert from Molloy method used by Daly et al. (1995) and Crider 
et al. (2014) to Pfeiffer/NHANES method, the following conversion formula should be used: 
Pfeiffer/NHANES RBC folate [nmol/L] = (Molloy RBC folate [nmol/L] * 0.7876) + 
34.2802 [nmol/L] (correlation r=0.92, n = 2613 paired samples) (Crider et al., 2014, Pfeiffer 
et al., 2011)) to allow comparison of NHANES values with the risk categories defined in the 
Daly et al. and Crider et al. studies (Pfeiffer et al., 2011; Crider et al., 2014). Optimal RBC 
folate concentrations for NTD prevention have been established by the World Health 
organization to be >906 nmol/L (400 ng/L), for purposes of this analysis we considered an 
optimal RBC folate concentration to be 748 nmol/L NHANES assay (~906 nmol/L Molloy 
assay), the concentrations associated with an NTD risk of <9 NTDs per 10,000 live births 
based on the results of the Daly et al. and Crider et al. studies (WHO, 2015).
COVARIATES
Supplement use was defined based on whether the participant reported consuming a folic 
acid-containing supplement in the past 30 days. Participants who reported supplement use 
were asked to provide the name of the supplement, frequency of use, and typical dose. 
NHANES staff matched the reported products to their ingredients using in-house databases 
and communication with supplement manufacturers. They then compiled this information 
and provided an estimated daily average dose of several nutrients, including folic acid 
(National Center for Health Statistics; National Center for Health Statistics; National Center 
for Health Statistics). Among women who reported consuming folic acid from supplements, 
we categorized them based on their average daily folic acid intake from supplements: ≥400 
µg and<400 µg; and among women who reported <400 µg, <200 µg and 200 to<400 µg. 
These values were chosen based on the recommendations that women of childbearing 
Tinker et al. Page 3













potential consume at least 400 µg/day for NTD prevention (Centers for Disease Control and 
Prevention, 1992; Institute of Medicine, 1998; U.S. Preventive Services Task Force, 2009) 
and to understand the distribution of average daily intake from supplements below the 
recommended level.
Dietary information on folic acid intake was collected with two 24-hr dietary recalls. Each 
food reported by each participant was linked to the U.S. Department of Agriculture’s 
(USDA) Food and Nutrient Database for Dietary Studies (Agricultural Research Service and 
Group, 2010; Ahuja et al., 2012; U.S. Department of Agriculture and Agricultrual Research 
Service, 2014). We created four mutually exclusive folic acid intake groups: (1) those who 
reported only consuming folic acid from enriched cereal grain products (ECGP only), (2) 
those who reported consuming ECGP and ready-to-eat (RTE) cereals that contained folic 
acid (ECGP + RTE), (3) those who reported consuming ECGP and dietary supplements 
(SUPP) that contained folic acid (ECGP + SUPP), and (4) those who reported consuming all 
three sources (ECGP + RTE + SUPP). Participants who reported consuming any RTE cereal 
(USDA food codes: 57000000–57419000) that contained folic acid on either day 1 or day 2 
of the dietary recall were classified as RTE cereal consumers. If no consumption of RTE 
cereals or supplements containing folic acid was reported, the participant was assumed to 
consume folic acid only from ECGP, as it is the only other major source of folic acid in the 
United States.
Data on age, race/ethnicity, education, and poverty income ratio (PIR) were also collected 
during the in-home interview. We created three age group categories: 12 to 24 years, 25 to 
34 years, and 35 to 49 years. Participants were categorized by NHANES based on their self-
reported race/ethnicity as either non-Hispanic white, non-Hispanic black, Mexican 
American, Other Hispanic, or Other race/ethnicity. For our analysis, participants who 
classified themselves as either Mexican American or Other Hispanic were combined to form 
a Hispanic category. We did not analyze data for the Other race/ethnicity category because 
of the heterogeneity of that group; women in this category were included in all analyses 
except those stratified by race/ethnicity. We created three categories for educational 
attainment (<high school, high school graduate or equivalent, >high school). We created 
four categories of poverty income ratio (PIR), which is defined as the ratio of self-reported 
family income to federal poverty threshold, accounting for family size, year, and state; 
higher values correspond to higher socioeconomic (National Center for Health Statistics; 
National Center for Health Statistics).
Weight and height were measured during the physical examination at the MEC and BMI 
was calculated (weight (kg)/height (m)2). Individuals were classified as underweight 
(BMI<18.5), normal weight (18.5≤BMI<25), overweight (25≤BMI<30), or obese (BMI≥30) 
(National Heart Lung and Blood Institute, 2000). Smoking status was determined using 
serum cotinine concentrations from samples taken at the MEC. Women with cotinine 
concentrations >10 ng/ml were classified as smokers (Pirkle et al., 1996).
STATISTICAL ANALYSIS
We estimated the weighted percentage of our total study population that was categorized 
into each of the previously defined groups. We estimated geometric mean RBC folate 
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concentrations for each of these groups, adjusting for age, race/ethnicity, and BMI 
categories. We used chi-square tests and t tests to assess statistical differences; we 
considered p-values <0.05 to be statistically significant. We used multivariable logistic 
regression to estimate adjusted odds ratios for factors potentially associated with having a 
suboptimal RBC folate concentration for NTD prevention (i.e., <748 nmol/L), again 
adjusting for age, race/ethnicity, and BMI. We used SAS-Callable SUDAAN Version 11.0 
(Research Triangle Park, NC) to account for the complex sampling design of NHANES. The 
estimates accounted for weighting and design factors according to NCHS guidelines 
(National Center for Health Statistics, 2006).
Results
Use of a dietary supplement containing folic acid was reported by 28.5% (95% confidence 
interval [CI]: 26.2, 30.8) of women (Table 2). Among women who reported consuming a 
dietary supplement containing folic acid, approximately half reported an average dose of 
≥400 mg folic acid/day, representing 13.8% of all women (95% CI, 12.5–15.3). Almost half 
of women reported consuming folic acid only from ECGP (48.4%; 95% CI, 46.3–50.6). 
Only 10.3% of the women reported consuming all three sources of folic acid (95% CI, 8.8–
11.9).
Women who did not report taking a supplement containing folic acid had lower RBC folate 
concentrations than those who reported taking them, and higher average daily folic acid dose 
from supplements was associated with higher concentrations (Fig. 1). Approximately 10% 
of women who did not report use of a supplement containing folic acid had RBC 
concentrations corresponding to the high risk category for population NTD risk; with an 
additional 18% with RBC concentrations consistent with an elevated risk for NTDs (exact 
percentages are available in Supplementary Table S1, which is available online). Women 
who reported intake of folic acid only from ECGP had lower RBC concentrations than 
women who consumed folic acid from multiple sources (Fig. 2). Approximately 12% of 
women who consumed folic acid only from ECGP had RBC folate concentrations in the 
high risk categories, and an additional 20% had concentrations in the elevated risk category 
(Supplementary Table S1).
The adjusted geometric mean RBC folate concentration for nonpregnant women aged 12 to 
49 years of age was 992 nmol/L (95% CI, 973–1012) (Table 3). Although the majority of 
women had an RBC folate concentration corresponding to an NTD prevalence of <9 per 
10,000 live births, 22.8% (95% CI, 21.1–24.6) had RBC folate concentrations associated 
with higher NTD prevalence. We observed a substantial, statistically significant difference 
in the adjusted geometric mean RBC folate concentrations between women who did and did 
not report use of a dietary supplement containing folic acid (1176 nmol/L and 925 nmol/L, 
respectively). This difference translated to an almost 65% reduction in the odds of having 
suboptimal RBC folate concentrations for women who reported consuming any folic acid-
containing supplement (adjusted odds ratio [aOR]: 0.36; 95% CI, 0.30–0.44).
The adjusted geometric mean RBC folate concentrations were higher for women with higher 
average daily folic acid dose from dietary supplements (Table 3). Large, statistically 
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significant differences in adjusted geometric mean RBC folate concentrations were also 
observed when we considered groups defined by folic acid intake source. Women who 
reported consuming folic acid through only ECGP had an adjusted geometric mean RBC 
folate concentration of 889 nmol/L (95% CI, 863–916), while those who consumed folic 
acid from ECGP, RTE cereals, and supplements had an adjusted geometric mean of 1274 
nmol/L (95% CI, 1224–1326). The odds of having suboptimal RBC folate concentrations 
were significantly lower for women who reported consuming sources of folic acid in 
addition to ECGP, ranging from 46% lower for women who reported consuming ECGP and 
RTE cereals (aOR: 0.54; 95% CI, 0.44–0.66) to 82% lower for women who reported 
consuming ECGP, RTE cereals, and supplements (aOR: 0.18; 95% CI, 0.11–0.31), 
compared with women who consumed ECGP only.
Non-Hispanic white women had an adjusted geometric mean RBC folate concentration of 
1043 nmol/L (95% CI, 1022–1075), which was significantly higher than that of Hispanics 
(963 nmol/L; 95% CI, 934–982) and non-Hispanic blacks (829 nmol/L; 95% CI, 804–854) 
(Table 2). The adjusted geometric mean RBC folate concentration was significantly higher 
among older women; women with at least some college education; women with higher PIR; 
obese women; and nonsmokers. Use of supplements containing folic acid, intake of folic 
acid from sources in addition to ECGP, having at least some college educational experience, 
having a high PIR, and being obese were associated with significantly reduced odds of 
having suboptimal RBC folate concentrations (Table 3). Non-Hispanic black and Hispanic 
race/ethnicity and being a current smoker were associated with significantly increased odds 
of having suboptimal RBC folate concentrations. The distribution into NTD risk categories 
(i.e., high, elevated, optimal, limited additional benefit) based on RBC folate concentrations 
by dietary, demographic, and lifestyle factors is available in Supplementary Table S1.
Discussion
Our findings suggest that the majority of nonpregnant women aged 12 to 49 years have RBC 
folate concentrations associated with a risk of <9 NTDs per 10,000 live births. The 
proportion of women with suboptimal RBC folate concentrations differs by supplement use, 
sources of folic acid intake, race/ethnicity, socioeconomic status, BMI category, and 
smoking status. Overall, nearly a quarter of women (22.8%; 95% CI, 21.1–24.6) of 
childbearing age have suboptimal folate concentrations for NTD prevention. Among women 
who report consuming ECGP only, a third (32.5%; 95% CI, 28.7–36.6) have suboptimal 
RBC folate concentrations. Given that almost half of women report consuming ECGP only, 
this finding could have significant implications on the potential risk of NTD-affected 
pregnancies.
Fortification of ECGP has had a dramatic impact on RBC folate concentrations and rates of 
NTDs in the United States. RBC folate concentrations for women aged 15 to 44 years 
increased from 686 nmol/L in 1988 to 1994 (prefortification) to 1060 nmol/L in 1999 to 
2010 (postfortification) (Pfeiffer et al., 2012). Similarly, the decline in rates of NTDs 
(anencephaly and spina bifida) has been estimated to be 35% since fortification, with a 
similar decrease observed across racial/ethnic groups (Williams et al., 2015). Yet, there are 
still approximately 2500 to 3000 U.S. pregnancies affected by an NTD every year (Centers 
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for Disease Control and Prevention, 2004; Parker et al., 2010). Current U.S. 
recommendations for the prevention of NTDs are that women capable of becoming pregnant 
consume 400 mg of folic acid every day from supplements and fortified foods in addition to 
consuming a diet that is high in folate-rich foods (Centers for Disease Control and 
Prevention, 1992; Institute of Medicine, 1998; U.S. Preventive Services Task Force, 2009). 
However, evidence has suggested that on average nonpregnant women aged 15 to 44 years 
report consuming a median daily usual intake of 245 mg of total folic acid and less than a 
quarter report a usual intake ≥400 mg of folic acid every day (Tinker et al., 2010).
Results from two large U.S. retrospective case-control studies of NTDs conducted after the 
implementation of folic acid fortification suggest that folic acid supplement use in the 
presence of fortification of ECGP and RTE cereals is not associated with additional 
decreases in the risk of NTDs (Mosley et al., 2009; Ahrens et al., 2011). Our results are 
consistent with these findings. The majority of U.S. women of childbearing age, including 
those who do not take supplements containing folic acid, have RBC folate concentrations 
associated with the lowest (optimal) NTD risk. There is still a group of women with less-
than-optimal RBC folate concentrations, but it is relatively small and the majority of these 
women are in the elevated (not high) risk group, such that studies would need extremely 
large sample sizes to detect the residual impact of supplements in the presence of 
consumption of fortified ECGP for these women.
We observed that non-Hispanic black women had significantly lower RBC folate 
concentrations than non-Hispanic white women, which is consistent with previous data 
showing that non-Hispanic black women have lower estimated average daily usual total 
folic acid intake than non-Hispanic white women (Tinker et al., 2010). Despite lower folic 
acid intake and lower RBC folate concentrations, non-Hispanic black women have not been 
observed to be at higher risk for an NTD-affected pregnancy (Canfield et al., 2006; Williams 
et al., 2015). This apparent paradox has generally been attributed to a lack of genetic 
susceptibility (very low MTHFR genotype frequency <3%) (Yang et al., 2008) and high B12 
concentrations (20% higher than non-Hispanic whites) (Sternberg et al., 2013) which could 
allow for more efficient use of folate and possibly lower folate requirements and/or less 
folate vitamers present in the folate pools, making measurement of folate status more 
difficult. The categories of NTD risk defined by RBC folate concentration used in our 
analysis were based on data from Irish and Chinese populations, and it is possible that these 
categories may not be appropriate for all racial/ethnic groups.
LIMITATIONS
Our analyses are subject to several additional limitations. The NTD risk categories based on 
RBC folate concentrations were derived from the Daly et al. and Crider et al. studies (Daly 
et al., 1995; Crider et al., 2014). These risk estimates have uncertainty associated with them 
and although mutually exclusive categories of NTD risk (Table 1) are useful for descriptive 
analysis, they fail to convey this imprecision. Additionally, the microbiologic assay 
technique used by NHANES differs from that used in the Daly et al. (1995) and Crider et al. 
(2014) studies and results in nonequivalent RBC folate concentrations; we therefore 
converted the RBC concentration values between the studies to ensure comparability. 
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Although a conversion equation is available and correlation between the assays, based on 
comparison of >2600 samples, is high (r = 50.92) (Pfeiffer et al., 2011; Crider et al., 2014) 
we were not able to account for uncertainty in this conversion in our analysis. In addition, 
we categorized women by their reported average daily dose of folic acid from supplements; 
however, supplement use was based on the previous 30 days and might not be reflective of 
long-term supplement use across the population. We also might have misclassified some 
RTE cereal consumers if they did not report consuming these on either day 1 or day 2 of the 
dietary recall. The use of data from NHANES is a major strength of this study; NHANES 
data are nationally representative and provide information on dietary, demographic, and 
lifestyle factors as well as biological samples.
CONCLUSIONS
In the presence of mandatory folic acid fortification and current folic acid supplementation 
patterns we would predict that the majority of U.S. women of reproductive age are not at 
increased risk for folate-sensitive NTDs based on RBC folate concentrations. However, the 
data presented here allow us to identify U.S. women with different dietary, lifestyle and 
sociodemographic characteristics that put them at higher risk for having a pregnancy 
affected by a folate sensitive NTD. Policies and programs aimed at these at-risk groups can 
help increase RBC folate concentrations through a variety of methods, including promoting 
the consumption of fortified foods or increasing awareness of the importance of taking a 
supplement containing folic acid, in addition to consuming a diet that is high in naturally 
folate-rich foods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Cumulative distribution of red blood cell (RBC) folate concentrations among nonpregnant 
women aged 12 to 49 years, by supplement use and folic acid dose, NHANES 2007 to 2012.
NTDs, neural tube defects.
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Cumulative distribution of red blood cell (RBC) folate concentrations among nonpregnant 
women aged 12 to 49 years, by folic acid source(s), NHANES 2007 to 2010. NTDs, neural 
tube defects; ECGP, enriched cereal grain products; RTE, ready-to-eat cereals; SUPP, 
dietary supplements containing folic acid.
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TABLE 1
Neural tube defect (NTD) risk category by red blood cell (RBC) folate concentrations for different blood 
folate assay methods1
Risk category NTD prevalence per
10,000 live births2
RBC folate concentration (nmol/L)
Molloy method Pfeiffer/NHANES
method3
High >14 ≤699 ≤585
Elevated 9 – 14 700 – 905 586 – 747
Optimal 4 – <9 906 – 1499 748 – 1215
Limited additional benefit Outside of estimable range ≥1500 ≥1216
1
Derived from Crider et al., 2014 (1) and Daly et al., 1995 (2)
2
NTD prevalence estimates are based on the median estimated NTD prevalence for an entire population with a given RBC folate concentration, 
corresponding to the risk category cut points; rounded to the nearest whole number
3
To convert from Molloy method to Pfeiffer/NHANES method, the following conversion formula should be used: Pfeiffer/NHANES RBC folate 
[nmol/L] = (Molloy RBC folate [nmol/L] * 0.7876) + 34.2802 [nmol/L] (1)
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TABLE 2
Characteristics of women aged 12–49 years by selected dietary, demographic, and lifestyle factors, NHANES 
2007–2010
Unweighted count Weighted percentage
(95% Confidence Interval)
Total1 3,861
Use of supplements containing folic acid
None 2,965 71.2 (68.2, 73.9)
Any 896 28.8 (26.1, 31.8)
Average daily dose <400µg 454 14.0 (12.3, 15.8)
Average daily dose<200 µg 236 7.2 (6.0, 8.7)
Average daily dose 200 - <400 µg 218 6.8 (5.7, 8.0)
Average daily dose ≥400 µg 442 14.9 (13.0, 16.9)
Folic acid source(s)2
ECGP only 1,728 47.5 (44.8, 50.3)
ECGP + RTE 921 24.1 (22.1, 26.4)
ECGP + SUPP 516 17.8 (15.9, 19.8)
ECGP + RTE + SUPP 290 10.6 (8.7, 12.8)
Age group
12 – 24 years 1,488 32.0 (29.9, 34.2)
25 – 34 years 868 24.4 (22.5, 26.4)
35 – 49 years 1,505 43.6 (41.4, 45.6)
Race/ethnicity
Non-Hispanic white 1,555 63.1 (57.3, 68.4)
Non-Hispanic black 767 13.2 (10.9, 15.9)
Hispanic 1,325 16.8 (13.1, 21.3)
Other race/ethnicity3 214 7.0 (5.4, 8.9)
Education level
< High school 1,591 30.9 (29.0, 32.9)
High school graduate/GED 666 17.7 (16.2, 19.2)
At least some college 1,600 51.5 (48.8, 54.1)
Poverty income ratio4
<1.0 1,029 20.4 (18.1, 23.0)
1.0 – 1.9 998 21.7 (19.4, 24.2)
2.0 – 3.9 817 27.2 (25.1, 29.5)
≥4.0 712 30.6 (27.1, 34.5)
Body Mass Index (BMI) [kg/m2]
Underweight (BMI<18.5) 196 4.8 (3.9, 5.9)
Normal weight (18.5≤BMI<25) 1,449 41.3 (39.2, 43.4)
Overweight (25≤BMI<30) 967 24.9 (23.0, 26.8)
Obese (BMI≥30) 1,202 29.1 (27.3, 30.9)
Smoking status5













Tinker et al. Page 15
Unweighted count Weighted percentage
(95% Confidence Interval)
Non-smoker 3,014 77.8 (75.1, 80.3)
Smoker 817 22.2 (19.7, 24.9)
NHANES: National Health and Nutrition Examination Survey; ECGP: Enriched cereal grain products; RTE: ready-to-eat cereals; SUPP: dietary 
supplements containing folic acid; GED: General Education Development, equivalent to high school degree
1
Excludes those who did not attend the Mobile Examination Center (N = 93), those for whom RBC folate concentration was missing (N=293), and 
those who reported that they did not know how many supplements they had taken (N = 1).
2
Additionally excludes those for whom the day 1 dietary recall was not reliable (N = 2) or missing (N = 147) and additionally those for whom the 
day 2 dietary recall was not reliable (N = 14) or missing (N = 438)
3
Other non-Hispanic race/ethnicity category not considered in subsequent analysis stratified by race/ethnicity due to heterogeneity within the 
category; women in this category are not excluded from other analyses
4
Poverty income ratio is defined as the ratio of self-reported family income to federal poverty threshold, accounting for family size, year, and state; 
higher values correspond to higher socioeconomic status
5
Smoking status is defined as non-smoker for serum cotinine concentrations ≤10 ng/mL and smoker for serum cotinine concentrations >10 ng/mL
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